Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III, open-label, randomized, multicenter, global trial of Pelareorep in combination with Paclitaxel in patients with advanced/ metastatic breast cancer

Next Previous
Search
Trial Profile

Phase III, open-label, randomized, multicenter, global trial of Pelareorep in combination with Paclitaxel in patients with advanced/ metastatic breast cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Pelareorep (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Adlai Nortye

    • Most Recent Events

    • 27 Jan 2022 According to a Vaccinex media release,The bridging clinical trial is designed to satisfy Chinese regulatory requirements and thereby accelerate pelareorep's development in territories that include China, Hong Kong, and Macau. Results from the trial are expected to allow Adlai Nortye to include data from Oncolytics' randomized North American metastatic breast cancer trials in future submissions to regulators in China and its territories.
    • 27 Jan 2022 According to a Vaccinex media release, company has advanced to the second of three dose escalation cohorts in this trial. Dosing in the trial's first dose escalation cohort is complete and no safety issues have been reported. The second dose escalation cohort is the equivalent dose that was administered in the IND-213 study
    • 14 Oct 2021 According to an Oncolytics Biotech media release, first patient has been dosed in this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top